NCT02686008撤回1 期
A Pilot Pharmacodynamic Study to Assess the Anti-proliferative Activity a of the Poly ADP Ribose Polymerase (PARP) Inhibitor Olaparib in Patients With Human Papilloma Virus (HPV) Positive and Human Papilloma Virus (HPV) Negative Head and Neck Squamous Cell Carcinoma (HNSCC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 主要终点
- Change in Level of IHC-Ki-67 expression
研究概览
简要总结
This is an open label pilot study evaluating the pharmacodynamics and safety of single agent olaparib administered at 300mg bid (twice a day) for 14 days orally in patients with human papillomavirus (HPV) -positive and human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC)
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed HNSCC with surgically resectable disease
- •No prior chemotherapy or radiation therapy as treatment for the observed HNSCC
- •Patients must provide written informed consent
- •Age >=18 years of age
- •Eastern Cooperative Oncology Group (ECOG) Performance Status score of <2
- •Normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below:
- •Hemoglobin >= 10 g/dL and no blood transfusions in the 28 days prior to entry/randomization
- •Absolute neutrophil count >=1.5 x 10^9/L
- •No features suggesting of MDS/AML on peripheral blood smear
- •White blood cells > 3 x 10^9/L
- •Platelet count >= 100 x 10^9/L
- •Total bilirubin <= 1.5 x institutional upper limit of normal (ULN)
- •AST (SGOT)/ALT (SGPT) < 2.5 x institutional upper limit of normal unless liver metastases are present in which case it must be < 5x ULN
- •Serum creatinine <= 1.5 x institutional ULN OR creatinine clearance >= 50 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
- •Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of the study participation and must have negative serum or urine pregnancy test within 1 week prior to beginning treatment on this trial
- •Must be abler to understand and sign a written informed consent document
排除标准
- •Patients with known brain metastases. Patients may have received WBRT within 14 days or focal radiation within 1 week of cycle 1, day
- •The patient can receive a stable dose of corticosteroids before and during the study as long as these were started at least 28 days prior to treatment
- •Women must not be pregnant or breastfeeding
- •Patients with known hypersensitivity to olaparib or any of the excipients of the product
- •Patients receiving any other investigational agents within 4 weeks of starting the study
- •Involvement in the planning and/or conduct of the study
- •Any previous treatment with a PARP inhibitor, including olaparib
- •Concomitant use of known CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin, and nelfinavir
- •Persistent toxicities (>=CTCAE grade 2)
- •Resting ECG with QTC >470msec on 2 or more time points within a 24 hour period or family history of long QT syndrome
- •Blood transfusions within 1 month prior to study start
- •Patients with myelodysplastic syndrome/acute myeloid leukemia
- •Major surgery within 14 days of starting study treatment and patients must have recovered from any effects of any major surgery
- •Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection.
- •Unable to swallow oral medication
- •Immunocompromised patients, e.g., patients who are known to be serologically positive for HIV and are receiving antiviral therapy
- •Known active hepatic disease
- •Uncontrolled seizures
- •Previous cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for 5 years
- •Currently on warfarin(subcutaneous heparin is permitted)
研究组 & 干预措施
HPV negative tumors
Experimental
10 patients with HPV negative tumors: Non-oropharyngeal tumors or p16 negative and HPV negative oropharyngeal tumors
干预措施: Olaparib (Drug)
HPV positive tumors
Experimental
10 patients with HPV positive tumors: p16 positive and HPV positive tumors
干预措施: Olaparib (Drug)
结局指标
主要结局
Change in Level of IHC-Ki-67 expression
时间窗: Baseline and 14 days
Tissue biopsy sections will be analyzed for proliferation (IHC-Ki-67) Ki-67 is a nuclear non-histone protein that is present at low levels in quiescent cells but is increased in proliferating cells. Thus, Ki-67 reactivity, defined as percent tumor cells staining positive as measured by immunohistochemical (IHC) staining, is a specific nuclear marker for cell proliferation.
次要结局
- Change in Tissue apoptosis(Baseline and 14 days)
- Change in DNA repair pathways(Baseline and 14 days)
研究者
相似试验
撤回
1 期
Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)Advanced Solid TumorsNCT06719973EMD Serono Research & Development Institute, Inc.54
已完成
1 期
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a)Elevated Serum Lipoprotein(a)NCT04987320Amgen24
已完成
2 期
Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLIActivated PI3K-delta SyndromeNCT02593539GlaxoSmithKline5
已完成
1 期
Pharmacokinetics of Everolimus in Subjects With Hepatic InsufficiencyHepatic InsufficiencyNCT00968591Novartis Pharmaceuticals34
已完成
1 期
Study to Evaluate the Pharmacokinetics (Movement of Drugs Within the Body), Safety and Tolerability of Brazikumab in Healthy Chinese and White ParticipantsHealthy ParticipantsNCT05033431AstraZeneca48